InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Replimune Group, Inc.

REPL Clue Score21
United States Fiscal year ends March CIK 0001737953
$13.42 +2.91% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $13.42 −55.97% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 20 Jul 2018. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2017Operating income−9.6Net income−7.7Fiscal year 2018Operating income−19.2Net income−19.7Fiscal year 2019Operating income−30.9Net income−30.8Fiscal year 2020Operating income−56.2Net income−52.6Fiscal year 2021Operating income−80.0Net income−80.9EPS, diluted−1.75Fiscal year 2022Operating income−118.3Net income−118.0EPS, diluted−2.26Fiscal year 2023Operating income−177.1Net income−174.3EPS, diluted−2.99Fiscal year 2024Operating income−234.8Net income−215.8EPS, diluted−3.24Fiscal year 2025Operating income−261.6Net income−247.3EPS, diluted−3.07Fiscal year 2026Operating income−319.9Net income−313.9EPS, diluted−3.38
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Operating income −9.6 −19.2 −30.9 −56.2 −80.0 −118.3 −177.1 −234.8 −261.6 −319.9
Net income −7.7 −19.7 −30.8 −52.6 −80.9 −118.0 −174.3 −215.8 −247.3 −313.9
Growth
EPS, diluted n/a n/a n/a n/a −1.75 −2.26 −2.99 −3.24 −3.07 −3.38
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2017Operating cash flow−7.1Capital expenditure−0.2Free cash flow−7.3Fiscal year 2018Operating cash flow−16.0Capital expenditure−0.1Free cash flow−16.2Fiscal year 2019Operating cash flow−25.4Capital expenditure−2.6Free cash flow−28.0Fiscal year 2020Operating cash flow−60.6Capital expenditure−6.5Free cash flow−67.1Fiscal year 2021Operating cash flow−61.4Capital expenditure−2.4Free cash flow−63.8Fiscal year 2022Operating cash flow−82.2Capital expenditure−2.3Free cash flow−84.5Fiscal year 2023Operating cash flow−128.1Capital expenditure−2.3Free cash flow−130.3Fiscal year 2024Operating cash flow−185.5Capital expenditure−5.7Free cash flow−191.1Fiscal year 2025Operating cash flow−192.3Capital expenditure−6.7Free cash flow−198.9Fiscal year 2026Operating cash flow−280.3Capital expenditure−4.2Free cash flow−284.6
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Operating cash flow −7.1 −16.0 −25.4 −60.6 −61.4 −82.2 −128.1 −185.5 −192.3 −280.3
Capital expenditure −0.2 −0.1 −2.6 −6.5 −2.4 −2.3 −2.3 −5.7 −6.7 −4.2
Free cash flow −7.3 −16.2 −28.0 −67.1 −63.8 −84.5 −130.3 −191.1 −198.9 −284.6
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2017Cash20.7Shareholders’ equity−11.5Fiscal year 2018Cash17.6Shareholders’ equity−28.1Fiscal year 2019Cash25.7Shareholders’ equity137.9Fiscal year 2020Cash59.5Total debt9.8Net cash (debt)49.7Shareholders’ equity183.7Debt to equity0.05Fiscal year 2021Cash182.5Shareholders’ equity498.7Fiscal year 2022Cash105.9Total debt0.0Net cash (debt)105.9Shareholders’ equity411.2Debt to equity0.00Fiscal year 2023Cash146.6Total debt28.6Net cash (debt)117.9Shareholders’ equity555.3Debt to equity0.05Fiscal year 2024Cash74.5Total debt44.8Net cash (debt)29.6Shareholders’ equity374.5Debt to equity0.12Fiscal year 2025Cash111.1Total debt46.4Net cash (debt)64.7Shareholders’ equity415.8Debt to equity0.11Fiscal year 2026Cash209.0Total debt83.3Net cash (debt)125.7Shareholders’ equity166.2Debt to equity0.50
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Cash 20.7 17.6 25.7 59.5 182.5 105.9 146.6 74.5 111.1 209.0
Total debt n/a n/a n/a 9.8 n/a 0.0 28.6 44.8 46.4 83.3
Net cash (debt) n/a n/a n/a 49.7 n/a 105.9 117.9 29.6 64.7 125.7
Shareholders’ equity −11.5 −28.1 137.9 183.7 498.7 411.2 555.3 374.5 415.8 166.2
Debt to equity n/a n/a n/a 0.05 n/a 0.00 0.05 0.12 0.11 0.50

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2026 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending March, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2017 31 Mar 2017 FY2018 31 Mar 2018 FY2019 31 Mar 2019 FY2020 31 Mar 2020 FY2021 31 Mar 2021 FY2022 31 Mar 2022 FY2023 31 Mar 2023 FY2024 31 Mar 2024 FY2025 31 Mar 2025 FY2026 31 Mar 2026
Revenue and profit
6.9 13.5 22.2 38.8 56.8 79.5 126.5 175.0 189.4 221.2
2.7 5.7 8.8 17.4 23.2 38.8 50.6 59.8 72.2 98.7
−9.6 −19.2 −30.9 −56.2 −80.0 −118.3 −177.1 −234.8 −261.6 −319.9
Growth
−7.7 −19.7 −30.8 −52.6 −80.9 −118.0 −174.0 −215.4 −246.8 −314.5
0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.4 0.5 −0.6
−7.7 −19.7 −30.8 −52.6 −80.9 −118.0 −174.3 −215.8 −247.3 −313.9
Growth
Per share
n/a n/a n/a n/a −1.75 −2.26 −2.99 −3.24 −3.07 −3.38
n/a n/a n/a n/a −1.75 −2.26 −2.99 −3.24 −3.07 −3.38
Growth
n/a n/a n/a n/a 46.2 52.2 58.2 66.6 80.6 92.8
n/a n/a n/a n/a 46.2 52.2 58.2 66.6 80.6 92.8
Growth +12.9% +11.5% +14.4% +21.0% +15.2%

Five years in brief

Worked out from the figures above, not from a press release
  • The diluted share count rose 100.7% in five years, which is dilution.
  • A net loss in 10 of 10 years on file.